Journal
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
Volume 19, Issue 2-3, Pages 82-85Publisher
KARGER
DOI: 10.1159/000082353
Keywords
quality of life; dementia; psychotropic drugs
Categories
Funding
- NIA NIH HHS [AG12300] Funding Source: Medline
- NATIONAL INSTITUTE ON AGING [P30AG012300] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Background: We report on the responsiveness of a previously validated quality-of-life scale, the Quality of Life in Late-Stage Dementia scale (QUALID), as an outcome measure in a clinical trial of two psychotropic medications. Methods: Secondary analyses were conducted comparing outcome measures used in a randomized double-blind trial of two antipsychotics ( olanzapine and risperidone) for the treatment of dementia-related behavioral symptoms. The QUALID was completed for 31 of the patients in addition to several measures of behavior-related dementia symptoms including the Neuropsychiatric Inventory, the Withdrawn Behavior subscale of the Multidimensional Observation Scale for Elderly Subjects, the Mini-Mental State Examination, and the Clinical Global Impression. Measures of safety and adverse effects included the Simpson-Angus Scale and records of specific adverse events. Results: A significant positive relationship was found between QUALID score and improvement in behavioral symptoms, and a negative association was found with adverse medication effects. Conclusions: The QUALID was sensitive to both the treatment effects and the adverse effects of medication in this sample of patients. Copyright (C) 2005 S. Karger AG, Basel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available